CuroNZ Gets Infusion Of Funds To Test Peptides For Treating MS
This article was originally published in PharmAsia News
New Zealand's CuroNZ, a biotech startup, has received just more than $451,000 from the U.S. National Multiple Sclerosis Society to begin pre-clinical studies of neural regeneration peptides for treating the disease.
You may also be interested in...
France has announced a number of emergency measures to protect drug supplies threatened by the spread of the coronavirus.
Major generics companies have donated hydroxychloroquine sulfate doses for research and treatment of coronavirus. Companies are also donating hand sanitizer and personal protective equipment and are preparing to ramp up manufacturing and production.
Inovio forges ahead into Phase I trials with DNA-based vaccine candidate, but can it prove skeptics wrong?